Name: Anti-Human CD25 (Daclizumab Biosimilar)
Brand: InnoCyto
SKU: 501702
Price: 750 USD
Availability: InStock

Shop Now Contact

Anti-Human CD25 (Daclizumab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
501701	1 mg	$250
501702	5 mg	$750
501703	20 mg	$2000

Bulk/Custom

Product Details

Clone	Daclizumab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Anti-Human CD25 (Daclizumab Biosimilar)
Isotype	Human IgG1
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human CD25
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Synonyms	IL-2Ra, IL-2 Receptor alpha
Target Name	IL-2 receptor α chain, Low affinity IL-2R, IL-2Rα chain
Antibody Type	Recombinant
Research Areas	T cells, Tregs, T cell Activation, Adaptive Immunity, Autoimmunity, Cancer Marker, Dendritic cells
See All Formats	Clone Daclizumab

Background Information

Daclizumab is a humanized monoclonal antibody that belongs to the immunoglobulin G1 (IgG1) subclass and was engineered to selectively bind to the interleukin-2 receptor alpha chain (IL-2Rα, also known as CD25) on the surface of activated T lymphocytes. Structurally, it is composed of two identical heavy chains and two identical light chains connected by disulfide bonds to form the characteristic Y-shaped antibody configuration. The molecule has a molecular weight of approximately 144 kilodaltons (kDa) and is produced using recombinant DNA technology in mammalian expression systems, ensuring proper folding, glycosylation, and disulfide linkage formation.

The variable domains of the heavy (VH) and light (VL) chains in Daclizumab contain complementarity-determining regions (CDRs) derived from murine antibody sequences that confer antigen-binding specificity. These CDRs form the paratope, which recognizes and binds with high affinity to an epitope on the IL-2Rα subunit. The constant regions of the antibody are of human origin, resulting in a humanized structure that maintains antigen specificity while enhancing stability and reducing non-native immunogenic residues. When Daclizumab engages CD25, it sterically hinders the binding of interleukin-2 (IL-2) to its high-affinity receptor complex (composed of CD25, CD122, and CD132 subunits). This interruption modulates downstream signaling cascades involving the JAK-STAT pathway, thereby influencing T-cell proliferation and activation in experimental systems that model cytokine signaling.

The Fc domain of Daclizumab, characteristic of IgG1 molecules, contributes to molecular stability, prolongs systemic persistence through interaction with the neonatal Fc receptor (FcRn), and allows potential binding to Fc gamma receptors (FcγRs) with limited effector function. The antibody’s glycosylation at conserved asparagine residues within the CH2 domain supports proper structural conformation and solubility. Overall, Daclizumab exemplifies a rationally engineered monoclonal antibody that combines precise receptor targeting with optimized immunoglobulin architecture to elucidate cytokine-receptor signaling and T-cell regulation mechanisms in molecular immunology research.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips